ADMA Biologics
ADMA · Biotechnology
$10.68
2.5%Arrowhead Pharmaceuticals
ARWR · Biotechnology
$58.02
0.6%The short version
- Arrowhead Pharmaceuticals is the larger business, with $829M of revenue in fiscal 2025 against $510M for ADMA Biologics, about 1.6 times as much.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 19.6%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against 11.9% operating margin).
- Arrowhead Pharmaceuticals turned more of its sales into free cash flow (18.9% FCF margin, against 5.5% FCF margin).
| Latest fiscal year | ADMA · FY25 | ARWR · FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | $8.3B |
| Revenue | $510M | $829M |
| Free cash flow | $27.8M | $157M |
| Net income | $147M | −$1.6M |
| Growth | ||
| Revenue growth | 19.6% | 23,258.2% |
| 5-year growth | 64.6% | 56.6% |
| Share count change | 0.6% | 11.7% |
| Profitability | ||
| Gross margin | 57.4% | — |
| Operating margin | 37.5% | 11.9% |
| Net margin | 28.8% | −0.2% |
| FCF margin | 5.5% | 18.9% |
| Return on capital | 39.5% | — |
| Return on equity | 35.6% | −0.5% |
| Balance sheet | ||
| Net debt | −$15.5M | −$665M |
| Net debt / EBITDA | −0.1x | −5.5x |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | — |
| Piotroski F-score | 5 | 5 |
FY16
ADMA $10.7M
ARWR $0.2M
FY17
ADMA $22.8M
ARWR $31.4M
FY18
ADMA $17.0M
ARWR $16.1M
FY19
ADMA $29.3M
ARWR $169M
FY20
ADMA $42.2M
ARWR $88.0M
FY21
ADMA $80.9M
ARWR $138M
FY22
ADMA $154M
ARWR $243M
FY23
ADMA $258M
ARWR $241M
FY24
ADMA $427M
ARWR $3.6M
FY25
ADMA $510M
ARWR $829M
ADMA
ARWR
FY16
ADMA −162.6%
ARWR −51,627.1%
FY17
ADMA −172.7%
ARWR −117.8%
FY18
ADMA −355.0%
ARWR −346.5%
FY19
ADMA −141.1%
ARWR 36.3%
FY20
ADMA −153.8%
ARWR −105.9%
FY21
ADMA −72.1%
ARWR −107.8%
FY22
ADMA −25.6%
ARWR −73.4%
FY23
ADMA 8.4%
ARWR −85.2%
FY24
ADMA 32.6%
ARWR −16,927.1%
FY25
ADMA 37.5%
ARWR 11.9%
ADMA
ARWR
FY16
ADMA −$18.3M
ARWR −$68.3M
FY17
ADMA −$40.0M
ARWR −$31.9M
FY18
ADMA −$64.8M
ARWR −$48.6M
FY19
ADMA −$80.0M
ARWR $161M
FY20
ADMA −$115M
ARWR −$108M
FY21
ADMA −$126M
ARWR $148M
FY22
ADMA −$73.4M
ARWR −$189M
FY23
ADMA $4.0M
ARWR −$331M
FY24
ADMA $110M
ARWR −$604M
FY25
ADMA $27.8M
ARWR $157M
ADMA
ARWR
FY16
ADMA —
ARWR —
FY17
ADMA —
ARWR −82.4%
FY18
ADMA —
ARWR −70.2%
FY19
ADMA —
ARWR 136.1%
FY20
ADMA −82.2%
ARWR −57.6%
FY21
ADMA −29.7%
ARWR −71.2%
FY22
ADMA −15.8%
ARWR −69.1%
FY23
ADMA 8.1%
ARWR −167.1%
FY24
ADMA 52.2%
ARWR —
FY25
ADMA 39.5%
ARWR —
ADMA
ARWR
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.